TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials

(2021) F. Pietrantonio et al.   ESMO Open

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.

(2020) Heinz-Josef Lenz et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

(2020) Robin Kate Kelley et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer

(2020) Kaysia Ludford et al.   JNCI-Journal of the National Cancer Institute

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

(2020) Myriam Chalabi et al.   NATURE MEDICINE

Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series

(2020) Zhening Zhang et al.   EJSO

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).

(2019) Eric Xueyu Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

The promise of neoadjuvant immunotherapy and surgery for cancer treatment

(2019) Jake S O'Donnell et al.   CLINICAL CANCER RESEARCH

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

(2019) Salah-Eddin Al-Batran et al.   LANCET

Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer

(2019) Filippo Pietrantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer

(2018) Yoon Young Choi et al.   ANNALS OF SURGERY

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

(2018) Kohei Shitara et al.   LANCET

Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis

(2018) Jae-Ho Cheong et al.   LANCET ONCOLOGY

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

(2018) Seung Tae Kim et al.   NATURE MEDICINE

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

(2018) Charles S. Fuchs et al.   JAMA Oncology

Abstract CT104: Evaluation of peripheral T cell subset proliferation as a pharmacodynamic assay to guide the development of anti-CTLA-4 and PD-1 antibody combinations in patients with solid tumors

(2018) Paul De Souza et al.   CANCER RESEARCH

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination

(2017) Arash Memarnejadian et al.   JOURNAL OF IMMUNOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Mismatch Repair Deficiency, Microsatellite Instability, and Survival

(2017) Elizabeth C. Smyth et al.   JAMA Oncology

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) E. C. Smyth et al.   ANNALS OF ONCOLOGY

Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology

(2016) Jaffer A. Ajani et al.   Journal of the National Comprehensive Cancer Network

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

(2016) Kei Muro et al.   LANCET ONCOLOGY

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy

(2016) I. Melero et al.   Cancer Discovery

Global Cancer Incidence and Mortality Rates and Trends--An Update

(2015) L. A. Torre et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

(2012) Yung-Jue Bang et al.   LANCET

Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer

(2010)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

(2010) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY